Results 1 to 10 of about 3,688,287 (401)

Associations of symptoms of anxiety and depression with health-status, asthma control, dyspnoea, dysfunction breathing and obesity in people with severe asthma

Respiratory Research, 2022
Background Anxiety and depression are comorbidities of severe asthma. However, clinical characteristics associated with coexisting severe asthma and anxiety/depression are poorly understood.
Michelle A. Stubbs, Vanessa L. Clark, Peter G. Gibson, Janelle Yorke, Vanessa M. McDonald   +4 more
doaj   +2 more sources

Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry

European Respiratory Journal, 2023
Background Novel biologic therapies have revolutionised the management of severe asthma with more ambitious treatment aims. Here we analyse the definition of clinical remission as a suggested treatment goal and consider the characteristics associated ...
P. McDowell, Ronald McDowell, John Busby, M. Eastwood, P. Patel, David J. Jackson, Adel H Mansur, M. Patel, Hassan Burhan, S. Doe, Rekha Chaudhuri, Robin Gore, James W. Dodd, Deepak Subramanian, Thomas Brown, L. Heaney, Chiesi. L.G. Heaney   +16 more
semanticscholar   +1 more source

Biologics and airway remodeling in severe asthma

Allergy. European Journal of Allergy and Clinical Immunology, 2022
Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in part can become irreversible to conventional therapies, defining the concept of airway remodeling.
G. Varricchi, S. Ferri, J. Pepys, R. Poto, G. Spadaro, E. Nappi, G. Paoletti, J. C. Virchow, E. Heffler, W. Canonica   +9 more
semanticscholar   +1 more source

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

Advances in Therapy, 2022
Consensus definitions for clinical remission and super-response were recently established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody for severe, uncontrolled asthma; efficacy and safety were ...
A. Menzies-Gow, F. Hoyte, D. Price, D. Cohen, P. Barker, J. Kreindler, M. Jison, Christopher L. Brooks, Peggy Papeleu, R. Katial   +9 more
semanticscholar   +1 more source

Assessing adherence to inhaled therapies in asthma and the emergence of electronic monitoring devices

European Respiratory Review, 2022
Infrequent use of inhaled corticosteroids (ICS) and/or over-reliance of short-acting β-agonists (SABA) are recognised as key contributors to increased morbidity and mortality in asthma.
Hetal Dhruve, David J. Jackson
doaj   +1 more source

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.

New England Journal of Medicine, 2021
BACKGROUND Children with moderate-to-severe asthma continue to have disease complications despite the receipt of standard-of-care therapy. The monoclonal antibody dupilumab has been approved for the treatment of adults and adolescents with asthma as well
L. Bacharier, J. Maspero, C. Katelaris, A. Fiocchi, R. Gagnon, I. de Mir, N. Jain, L. Sher, X. Mao, Dongfang Liu, Yi Zhang, Asif H Khan, U. Kapoor, F. Khokhar, P. Rowe, Y. Deniz, M. Ruddy, E. Laws, N. Patel, D. Weinreich, G. Yancopoulos, N. Amin, L. Mannent, D. Lederer, M. Hardin   +24 more
semanticscholar   +1 more source

Severe asthma [PDF]

Journal of Allergy and Clinical Immunology, 2006
Key pointsNot all patients with “difficult-to-control” asthma have “severe asthma”. Many of them have either an incorrect diagnosis, or mild-moderate asthma with unrecognised aggravating factors, or are non-compliant with prescribed therapy.For a diagnosis of severe asthma, it is necessary to confirm the diagnosis of asthma, to evaluate and treat ...
Susan, Foley, Qutayba, Hamid
openaire   +3 more sources

A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment

Respiratory Medicine Case Reports, 2021
Severe eosinophilic asthma is associated with a heavy burden and impact on daily living in patients experiencing uncontrolled symptoms, exacerbations, and treatment side effects.
John Davison, Simon Doe
doaj   +1 more source

Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

Journal of Asthma and Allergy, 2022
Introduction International registries provide opportunities to describe use of biologics for treating severe asthma in current clinical practice.
A. Menzies-Gow, C. McBrien, B. Unni, C. Porsbjerg, M. Al‐Ahmad, C. Ambrose, K. Dahl Assing, A. von Bülow, J. Busby, B. Cosío, J. FitzGerald, E. Garcia Gil, S. Hansen, Liam G aHeaney, M. Hew, D. Jackson, M. Kallieri, S. Loukides, N. Lugogo, A. Papaioannou, D. Larenas-Linnemann, W. Moore, L. Perez-de-Llano, L. Rasmussen, J. Schmid, Salman Siddiqui, M. Alacqua, T. Tran, C. Suppli Ulrik, J. Upham, E. Wang, L. Bulathsinhala, V. Carter, I. Chaudhry, N. Eleangovan, R. Murray, C. Price, D. Price   +37 more
semanticscholar   +1 more source

Severe Eosinophilic Asthma [PDF]

Journal of Clinical Medicine, 2019
Asthma is a heterogeneous disease with varying severity. Severe asthma is a subject of constant research because it greatly affects patients’ quality of life, and patients with severe asthma experience symptoms, exacerbations, and medication side effects.
Bakakos, A., Loukides, S., Bakakos, P.
openaire   +3 more sources